MCM
NKTR icon

Militia Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Militia Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.28M Buy
+90,000
New +$6.59M 0.19% 36

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Militia Capital Management's NKTR Position: Q2 2026 in Review

Militia Capital Management opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 90,000 shares worth $6.28M. The stake represents 0.19% of the portfolio and ranks #36 among its holdings.

219 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Militia Capital Management held 90,000 shares of Nektar Therapeutics worth $6.28M as of Q2 2026.
  • Nektar Therapeutics was a new Militia Capital Management position in Q2 2026.
  • Nektar Therapeutics made up 0.19% of Militia Capital Management's portfolio in Q2 2026, its #36 holding.
  • 219 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Militia Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.